Biotechnology · mRNA vaccines
Helix Nanotechnologies
An mRNA company that started on cancer, turned to COVID-19 in one week of March 2020, and took a single vaccine candidate into a first human study in Australia. No FDA approval, clearance or authorization appears on the public record.
Six days in March
On March 10, 2020, Hannu Rajaniemi was in New Brunswick, New Jersey, talking to a large pharmaceutical company he declined to name about the future of the industry. What he carried home was the thought that his own six person startup’s cancer work might apply to the virus then moving through the United States. By March 16 the turn was complete. Helix Nanotechnologies, a Cambridge lab founded in 2013 for cancer therapeutics, was a coronavirus vaccine company.
“Before March the 10th, before we decided to jump on this, I was definitely feeling very anxious,” he told CNBC in April 2020. Once the decision was made, the anxiety went away.
The money moved at the same speed. Rajaniemi told CNBC the company raised from its existing investors for the pivot in about 24 hours. On April 3, 2020, it injected its first coronavirus vaccine candidates into mice. Three weeks later he and co-founder Nikolai Eroshenko published a proposal for a ten billion dollar, DARPA style “Vaccine Manhattan Project” arguing that the eighteen month timeline everyone was quoting was a choice, not a law of nature.
The patients the first wave missed
The vaccines that arrived at the end of 2020 worked least well for the people who needed them most: transplant recipients, cancer patients on chemotherapy, anyone whose immune system is suppressed by drugs or disease and therefore responds weakly to the signal a vaccine sends.
That gap became HelixNano’s stated target. Its lead candidate, HN-0001, is described by the company as a second generation mRNA COVID-19 vaccine for immunosuppressed and immunocompromised people, resting on two patented ideas: a modified mRNA chemistry meant to improve tolerability, and a design element meant to raise the size of the immune response. Conventional vaccines, Rajaniemi said in 2021, show the immune system a piece of the virus and let the antibodies fall where they may. “Traditional vaccines are blunt instruments.” His company wanted to aim them.
In July 2020 Eroshenko, Rajaniemi, George Church and three colleagues published a piece in Nature Biotechnology on antibody dependent enhancement, the failure mode in which vaccine induced antibodies make a later infection worse rather than better. It is the only peer reviewed paper carrying the company’s people that a PubMed search returns.
A physicist who writes novels
Rajaniemi was born and raised in Finland and trained as a theoretical physicist. He is also a working science fiction writer whose following predates the company. In 2015 his mother died of metastatic breast cancer at 67, which is why, he has said, the company started on cancer. Eroshenko, the chief scientific officer, came out of the Harvard genetics world, and George Church chairs the scientific advisory board.
The investor list the company published on its own careers page is unusual for a lab that had nine employees in 2021: “HelixNano is backed by some of the world’s most visionary investors, including Y Combinator, Sam Altman, Chief Scientist of Google+DeepMind Jeff Dean, Thiel Capital, and Founders Fund.” Reuters reported in 2025 that Altman and OpenAI board member Nicole Seligman had invested.
Cambridge to Melbourne
In March 2021 Rajaniemi told CNBC the vaccine would go to clinical trials that year, with potential approval by early 2022, depending on many factors. It took longer. On March 20, 2024, the company announced that a wholly owned subsidiary, HelixNano Australia Pty Ltd of Melbourne, had Human Research Ethics Committee approval for a Phase 1 study of HN-0001 in healthy volunteers, with an approved vaccine comparator arm and first dosing anticipated that April.
The release is careful in a way company releases rarely are. It states that neither the US Food and Drug Administration nor the Australian Therapeutics Goods Administration has evaluated claims regarding HN-0001, and adds: “The efficacy and safety of HN-0001 has not been confirmed by approved research.”
The drug substance was made from synthetic DNA rather than the bacterial plasmid DNA most mRNA makers use. Its supplier, 4basebio, wrote in June 2025 that “Their initial clinical trial is nearly complete in Australia.” No results have been published.
The spinout
On November 13, 2025, Reuters reported that a new company, Red Queen Bio, had been spun out of Helix Nano with a fifteen million dollar seed round led by OpenAI. Its subject is AI biosecurity, not vaccines, and Rajaniemi is a co-founder. HelixNano’s own site now carries only a teaser: “What if a drug could design itself?”
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| FDA status | No 510(k), no PMA, and no approval, clearance or emergency use authorization for any HelixNano product in FDA databases as of Sep 23, 2026. No US investigational new drug application appears in any public source. | Not found |
| Trial registration | No registration for HelixNano or HN-0001 found on ClinicalTrials.gov. The single human study ran in Australia under ethics approval announced Mar 20, 2024, with the site to be activated after confirmation from the Australian Therapeutics Goods Administration. | Public record |
| Phase 1, as announced | Study CPHN-01 in healthy volunteers with an approved vaccine comparator arm, first dosing anticipated April 2024. A drug database recorded HN-0001 at Phase 1 in Australia as of Jun 6, 2024. | Company-stated |
| Phase 1, mid 2025 | Supplier 4basebio wrote in June 2025 that the trial was nearly complete. No results published, no completion announcement found. | Partner-stated |
| Peer reviewed literature | One PubMed result: Eroshenko, Gill, Keaveney, Church, Trevejo and Rajaniemi on antibody dependent enhancement and SARS-CoV-2 countermeasures, Nature Biotechnology, July 2020, PMID 32504046. No clinical results in the literature. | Public record |
| Patents | Grants assigned to Helix Nanotechnologies, Inc. include a fusion polypeptide and fusion mRNA patent filed Mar 3, 2022 and granted Oct 3, 2023, and a modified ribonucleotide patent covering N4-acetylcytidine and 5-hydroxymethyluridine. | Public record |
| Federal funding | No NIH or NSF award to Helix Nanotechnologies found. The company has described non federal grant support, including from Schmidt Futures. | Not found |
| Timeline claimed in 2021 | In March 2021 the CEO said the vaccine would reach trials in 2021 with potential approval by early 2022. Ethics approval for the first human study came in March 2024. No approval anywhere has been announced. | Differs from the record |
| Founders as reported | A trade database lists the company as founded in 2013 by Hannu Rajaniemi and Carina Namih. The company’s own December 2023 site lists Rajaniemi and Eroshenko as management and Namih as commercial advisor. | Sources disagree |
| Medicus Pharma collaboration | Announced Aug 4, 2025 as a non binding memorandum of understanding to explore a joint venture on thermostable, needle free vaccines. Medicus told the SEC on Mar 25, 2026 that “there can be no assurance that such definitive agreements will be executed.” | Public record |
| Regulatory or enforcement action | No FDA warning letter or enforcement action naming Helix Nanotechnologies or HelixNano found in FDA records or published reporting as of Sep 23, 2026. | Not found |
Read plainly: real patents, one peer reviewed paper, one first in human study conducted overseas, and no published clinical data. Everything known about how HN-0001 behaved in people rests on a supplier saying the trial was nearly finished, and on the company’s own preclinical account.
What to watch
- Results from the Australian Phase 1 of HN-0001.
- Whether the Medicus Pharma memorandum becomes a signed joint venture. It was still non binding in March 2026.
- Any US regulatory filing. There is no public evidence of one to date.
- Where the founders’ attention sits after Red Queen Bio, which raised fifteen million dollars in November 2025.
In their words
“This is not a side project, or a way to get some extra money from investors in a crisis: This is the mission”
Hannu Rajaniemi, co-founder and CEO, recalling what he told staff, CNBC, April 2020 · Independent
“We can make vaccines both more targeted and more powerful than was previously possible”
Hannu Rajaniemi, CNBC, March 2021 · Independent
“History teaches us that combining money with determined leadership can have an extraordinary effect on scientific and human progress. We have done this before for tools of war. Now let’s do it for tools of health.”
Nikolai Eroshenko and Hannu Rajaniemi, Six Months To A Vaccine, April 2020 · Company-stated
“The COVID-19 pandemic is not over, especially for the millions of immunosuppressed patients worldwide”
Hannu Rajaniemi, company release on Australian ethics approval, March 2024 · Company release
“The efficacy and safety of HN-0001 has not been confirmed by approved research.”
Legal statement in the company’s own March 2024 release · Company-stated
“It was clear that the biological capabilities were advancing faster than we anticipated”
Hannu Rajaniemi on founding Red Queen Bio, Reuters, November 2025 · Independent
Related companies
Sources
- Public recordNature Biotechnology, antibody-dependent enhancement and SARS-CoV-2 countermeasures, PMID 32504046
- Public recordPatents assigned to Helix Nanotechnologies, Inc.
- Public recordFDA 510(k) and PMA databases, ClinicalTrials.gov, NIH RePORTER, NSF awards
- Public recordEDGAR full text search, all forms and Form D only
- Public recordMedicus Pharma Ltd., Form 8-K exhibit 99.1, MOU with Helix Nanotechnologies Inc.
- Public recordMedicus Pharma Ltd., Form 10-K, collaborations section
- IndependentWhat it’s like to invent a coronavirus vaccine in the middle of a pandemic
- IndependentThis biotech start-up is working overtime to develop a second-wave, mutation-resistant Covid-19 vaccine, with its later correction notice
- IndependentOpenAI backs startup aiming to block AI-enabled bioweapons
- Trade databaseHelix Nanotechnologies company profile
- CompanyHelixNano Australia receives HREC approval to initiate a Phase 1 clinical trial
- CompanySix Months To A Vaccine: A New Manhattan Project for COVID-19
- CompanyHelixNano home page, Dec 2023 snapshot and current, and careers posting with investor list
- PartnerHelixNano accelerates mRNA vaccine development with synthetic DNA
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
